Avanos Medical, Inc.

Avanos Medical, Inc.

AVNSยทNYSE

$24.98

-0.060%
HealthcareMedical - Devices

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

At a Glance

Live Snapshot
Market Cap$1.17B
EPS-1.4600
P/E Ratio-17.11
Earnings Date08/04/2026

Intrinsic Alpha Methodology

Thesis Lenses

Signal ยท Driver ยท Risk

Signal

Medium confidence

Valuation multiple is compressed (P/E -17.1).

Valuation inputs: P/E -17.1, earnings yield N/A, momentum -0.1%.

If multiples stay elevated while momentum fades, downside repricing risk rises.

Driver

High confidence

Return profile is soft (ROE -8.7%, ROIC -6.7%).

Profitability stack: net margin -9.7%, ROE -8.7%, ROIC -6.7%.

Quality deterioration often appears in margins before it shows up in headline EPS.

Risk

High confidence

Risk profile is balanced but has notable pressure points to monitor.

Risk factors: liabilities/assets +27.5%, momentum -0.1%, net margin -9.7%.

Higher leverage with weak momentum and thin margins can amplify drawdown severity.

avns

Avanos Medical, Inc. Market vs Earnings Trajectory

AVNS ยท NYSE

Loading price and EPS data...

Avanos Medical, Inc.

Avanos Medical, Inc. Fair Value Envelope

AVNS ยท NYSE

Our analysis suggests that AVNS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $24.98, this represents a potential HIDDEN relative to our calculated worth for Avanos Medical, Inc..

Intrinsic Value
Current Price: $24.98
3Y-235.0%
5Y+156.0%
10Y-272.0%
3Y+2.0%
5Y-2.0%
10Y+24.0%
3Y-234.0%
5Y+150.0%
10Y-271.0%
3Y-18.0%
5Y-3088.0%
10Y-60.0%
3Y-40.0%
5Y-290.0%
10Y-73.0%
3Y-40.0%
5Y-36.0%
10Y-48.0%
Avanos Medical, Inc.

Avanos Medical, Inc. Profit Bridge

AVNS ยท NYSE
Revenue701.20M
Cost of Goods Sold (352.20M)
Gross Profit349.00M
Operating Expenses (410.60M)
Operating Income-61.60M
Interest Expense (4.00M)
Other Income/Expense-4.60M
Pretax Income-66.20M
Income Tax (1.70M)
Net Income-67.90M
Net Income
-67.90M

Profitability Analysis

Gross Margin

49.8%

Strong gross margins indicate healthy pricing and efficient production or service delivery.

Operating Margin

-8.8%

Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.

Net Profit Margin

-9.7%

Net losses indicate the company is burning cash. Sustainability depends on path to profitability.

Profitability Insight

Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.

49.77%
Gross Profit Margin
-10%
3Y-14.0%
5Y-9.0%
10Y-5.0%
-8.78%
Operating Profit Margin
-251%
3Y-243.0%
5Y-189.0%
10Y-28.0%
-9.68%
Net Profit Margin
-83%
3Y-231.0%
5Y+154.0%
10Y-238.0%
-8.73%
Return on Equity
-82%
3Y-323.0%
5Y+303.0%
10Y-342.0%
-6.32%
Return on Assets
-81%
3Y-324.0%
5Y+289.0%
10Y-429.0%
-6.65%
Return on Invested Capital
-275%
3Y-418.0%
5Y-417.0%
10Y+180.0%
AVNS

Avanos Medical, Inc. Cash Conversion Engine

AVNS ยท NYSE
Net Income-72.90M
Depreciation & Amortization38.90M
Stock-Based Compensation0.00
Change in Working Capital9.80M
Others98.90M
Capital Expenditures-31.60M
Free Cash Flow43.10M

Cash Flow Quality Analysis

FCF Conversion Rate

-59.1%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

42.3%

Capital-intensive operations require significant reinvestment. Monitor whether CapEx is maintenance or growth-oriented.

FCF Growth Trend

-48.0%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$9.80M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Cash Flow Quality Insight

Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.

avns

Avanos Medical, Inc. Funding & Solvency Profile

AVNS ยท NYSE
Cash & Cash Equivalents65.60M
Net Receivables103.00M
Inventory141.30M
Other Current Assets15.10M
Total Current Assets325 M
Property, Plant & Equipment150.50M
Goodwill & Intangible Assets508.70M
Long-Term Investments0.00
Other Non-Current Assets32.90M
Total Non-Current Assets183 M
Total Assets
1.05B

Financial Health Analysis

Current Ratio

2.48x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.34x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

194 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

31% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

avns

Avanos Medical, Inc. Street Expectations Map

AVNS ยท NYSE

Wall Street analysts project that AVNS stock may see slight declines over the coming 12 months. The consensus 1-year price target stands at 23.00, with estimates ranging from a low of 20.00 to a high of 26.00.

Lowest Target
20.00
-19.94%
Consensus Target
23.00
-7.93%
Highest Target
26.00
4.08%

The consensus 1-year price target stands at 23.00, with estimates ranging from a low of 20.00 to a high of 26.00.

Analyst Consensus Analysis

Upside Potential

-7.9%

Downside risk. Current price above analyst targets indicates potential overvaluation. Exercise caution and review catalysts.

Analyst Agreement

26.1% spread

Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.

Risk-Reward Profile

0.20x

Unfavorable risk-reward. Downside risk exceeds upside potential. Consider defensive positioning or alternative opportunities.

Analyst Conviction

Low

Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.

Market Sentiment Insight

Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.

avns

Avanos Medical, Inc. Insider Positioning

AVNS ยท NYSE

During the last 12 months, insiders have purchased $220K and sold $157K worth of AVNS shares, resulting in $63K of net buying activity.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

13.8K

152.17K

Net Activity

-152K

-$152K

9-12 Months

Bought

20.0K

219.50K

Sold

345

4.37K

Net Activity

+215K

+$215K

Top Buyers

1
BG

Blackford Gary

Director

20.0K sharesโ€ข1 transactions

$220K

Top Sellers

1
HK

Holbrook Kerr

Officer: Svp, Chief Commercial Officer

13.8K sharesโ€ข1 transactions

$152K

2
HJJ

Hurley John Joseph

Officer: Principal Accounting Officer

345 sharesโ€ข1 transactions

$4K

Insider Activity Analysis

Net Insider Sentiment

Bullish

Moderately bullish with $63K net buying. Insiders show cautious optimism through measured share purchases.

Buy/Sell Ratio

1.40:1

Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.

Insider Participation

Moderate Selling

2 insider sellers vs. 1 buyers. More insiders selling than buying suggests cautious or negative sentiment.

0.00%
Dividend Yield
3Y-
5Y-
10Y-
ย 

avns Dividend History

AVNS
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%